View older revisions Content changed at 2025-03-21, 1404/01/01

Protocol summary

Study aim
Determining the effect of umbilical cord serum drops in improving dry eye symptoms and the amount of epithelium regeneration in patients with dry eye syndrome.
Design
The clinical trial has a control group with two measurements in the follow-up and randomized block in three groups, Sjogren's patients and mustard gas chemical veterans, and phase 2 of the clinical trial is used on 30 patients.
Settings and conduct
The location of the study is the Eye Clinic of Baqiyatallah Hospital. In laboratory conditions, cord blood donor samples are screened for infectious viral pathogens such as human immunodeficiency virus, syphilis, and hepatitis B and C. Patient dry eye symptoms score, visual acuity, tear film breakup time, Schirmer test, fluorescein staining test of cornea and conjunctiva are evaluated and recorded to evaluate the amount of tissue damage before treatment and one month and 2 months after treatment.
Participants/Inclusion and exclusion criteria
Patients with Sjogren's syndrome and severe dry eyes, as well as chemical eye injuries caused by mustard gas, who do not respond well to conventional dry eye treatments will be included in the study. Patients who have infection and inflammation not related to dry eye, use of contact lenses, eye allergies, and a history of surgery and eyelid and eyelash abnormalities, as well as pregnant or breastfeeding women, will excluded in the study.
Intervention groups
In the intervention group, drops of umbilical cord blood serum are used to treat the symptoms of dry eyes and tissue destruction of the external surfaces of the eyes, and in the control group, conventional methods of dry eye treatment are used.
Main outcome variables
subjective symptoms of dry eyes; visual acuity; Tear film quality; staining of the cornea and conjunctiva

General information

Reason for update
Unfortunately, the study design was not stated correctly. There will be 3 groups in the study. One group of sjögren's patients who will receive the new drops, one group of sjögren's patients who will receive the conventional treatment drops and will be the control group for the previous group, and one group of mustard gas chemical veterans who will receive the new drops in one of their eyes and the conventional treatment drops in the other one and each person will be their own control. Also, the sample size was revised and there will be 10 people in each group.
Acronym
IRCT registration information
IRCT registration number: IRCT20230925059512N1
Registration date: 2024-08-11, 1403/05/21
Registration timing: prospective

Last update: 2025-03-21, 1404/01/01
Update count: 1
Registration date
2024-08-11, 1403/05/21
Registrant information
Name
Masoud Rostami
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 87 3444 7093
Email address
rostamimasoud7595@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-08-22, 1403/06/01
Expected recruitment end date
2025-03-21, 1404/01/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation effect of umbilical cord blood serum drops in the treatment of severe dry eye in patients with Sjogren's syndrome and mustard gas chemical veterans
Public title
Evaluation effect of umbilical cord blood serum drops in the treatment of severe dry eye
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients with Sjogren's syndrome and severe dry eyes, who do not respond well to conventional dry eye treatments chemical eye injuries caused by mustard gas and severe dry eyes, who do not respond well to conventional dry eye treatments low tear breakup time (less than 5 seconds) low Schirmer test results (5 mm) Positive fluorescein staining (≥3)
Exclusion criteria:
Patients who have infection and inflammation not related to dry eye use of contact lenses eye allergies history of surgery and eyelid and eyelash abnormalities pregnant or breastfeeding women
Age
No age limit
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size: 30
Randomization (investigator's opinion)
N/A
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Other
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Working Group/Ethics Committee in the Research of Baqiyatallah Al-Azam Medical Education Center
Street address
Mulla Sadra St., Baqiyatallah University of Medical Sciences
City
Tehran
Province
Tehran
Postal code
1435916471
Approval date
2024-06-29, 1403/04/09
Ethics committee reference number
IR.BMSU.BAQ.REC.1403.080

Health conditions studied

1

Description of health condition studied
1- Sjogren's syndrome patients with severe dry eyes 2- Mustard gas chemical veterans with severe dry eyes
ICD-10 code
H04.1
ICD-10 code description
Other disorders of lacrimal gland (Dry eye syndrome )

Primary outcomes

1

Description
Severe dry eye sign and symptoms
Timepoint
before the intervention and 1 and 2 months after the intervention
Method of measurement
The dry eye symptom score of the patient is subjectively used from the Persian OSDI questionnaire, whose validity and reliability have been checked in the Iranian population. Tear film breakup time test is evaluated using slit lamp with cobalt blue filter and sodium fluorescein. The Schirmer test is performed using a standardized kit containing a 5 x 30 mm filter paper strip and placed on the lower eyelid margin in the temporal area. Fluorescein staining test of cornea and conjunctiva is evaluated and recorded based on SICCA (Sjogren's International Collaborative Clinical Alliance) criteria to assess the amount of tissue damage before treatment and one month and 2 months after treatment.

Secondary outcomes

1

Description
Visual acuity status
Timepoint
Before the intervention and 1 and 2 months after the intervention, vision evaluation is done.
Method of measurement
We record the acuity of patients based on the logarithm of the minimum angle of resolution (log MAR) at each follow-up.

Intervention groups

1

Description
For the control group (Patients with Sjogren's syndrome and severe dry eye symptoms), conventional dry eye treatment methods such as artificial tear drops and topical corticosteroid drops are used and the changes are monitored. At first, the purpose of the study is simply explained and informed consent will be obtained from the participants.
Category
Treatment - Other

2

Description
Intervention group (Patients with Sjogren's syndrome and severe dry eye symptoms): After delivery, umbilical cord blood is collected immediately from expectant mothers in a sterile container without anticoagulants. Prior to procurement, respective umbilical cord donors must provide their written consent. In vitro, cord blood donor samples are screened for infectious viral pathogens such as human immunodeficiency virus (HIV), syphilis, and hepatitis B and C viruses. The collected virus-free umbilical cord blood is incubated for two to four hours at room temperature, after which the blood is centrifuged. After centrifugation, the yellow supernatant (serum) is carefully separated into a new sterile tube, and the remaining sediment of red blood cells and other cellular debris must be discarded. Heat inactivation should then be performed at 56°C for 30 minutes on collected serum followed by filtration and dilution to 20% storage at -20°C for future clinical use. Opened drops of serum should be kept in the refrigerator at a temperature of 4 degrees and unopened drops at a temperature of minus 20 degrees. Each opened drop is used for one week. Serum drops are used 4-6 times a day.
Category
Treatment - Drugs

3

Description
Intervention group (Right eye of the patients of mustard gas chemical veterans with severe dry eye symptoms): After delivery, umbilical cord blood is collected immediately from expectant mothers in a sterile container without anticoagulants. Prior to procurement, respective umbilical cord donors must provide their written consent. In vitro, cord blood donor samples are screened for infectious viral pathogens such as human immunodeficiency virus (HIV), syphilis, and hepatitis B and C viruses. The collected virus-free umbilical cord blood is incubated for two to four hours at room temperature, after which the blood is centrifuged. After centrifugation, the yellow supernatant (serum) is carefully separated into a new sterile tube, and the remaining sediment of red blood cells and other cellular debris must be discarded. Heat inactivation should then be performed at 56°C for 30 minutes on collected serum followed by filtration and dilution to 20% storage at -20°C for future clinical use. Opened drops of serum should be kept in the refrigerator at a temperature of 4 degrees and unopened drops at a temperature of minus 20 degrees. Each opened drop is used for one week. Serum drops are used 4-6 times a day.
Category
Treatment - Drugs

4

Description
For the control group (Left eye of the patients of mustard gas chemical veterans with severe dry eye symptoms), conventional dry eye treatment methods such as artificial tear drops and topical corticosteroid drops are used and the changes are monitored. At first, the purpose of the study is simply explained and informed consent will be obtained from the participants.
Category
Treatment - Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Eye Clinic of Baqiyatallah Hospital
Full name of responsible person
Seyyed Hashem Daryabari
Street address
MullaSadra St., Baqiyatallah University of Medical Sciences
City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 21 8755 4574
Email
rzfarnoosh@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Reza Kechui
Street address
MullaSadra St., Baqiyatallah University of Medical Sciences
City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 912 803 1247
Email
R.bmsu@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Bagheiat-allah University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Hossein Aghamolai
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Biotechnology
Street address
Mulla Sadra Street, Baqiyatullah University
City
Tehran
Province
Tehran
Postal code
1659966193
Phone
+98 21 8861 7711
Email
aghamolaei22@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Seyyed Hashem Daryabari
Position
Assistant Professor
Latest degree
Subspecialist
Other areas of specialty/work
Ophthalmology
Street address
Mulla Sadra Street, Baqiyatullah University
City
Tehran
Province
Tehran
Postal code
1659966193
Phone
+98 21 8861 7711
Email
shdarya50@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Masoud Rostami
Position
No Academic Degree
Latest degree
Master
Other areas of specialty/work
Optometry
Street address
Mulla Sadra Street, Baqiyatullah University
City
Tehran
Province
Tehran
Postal code
1659966193
Phone
+98 21 8861 7711
Email
rostamimasoud7595@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Loading...